Items where authors include "von Minckwitz, G"

Article

Kirschbrown, WP, Kagedal, M, Wang, B et al. (15 more authors) (2019) Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. Cancer Chemotherapy and Pharmacology, 83 (6). pp. 1147-1158. ISSN 0344-5704

Gray, R, Bradley, R, Braybrooke, J et al. (164 more authors) (2019) Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. The Lancet, 393 (10179). pp. 1440-1452. ISSN 0140-6736

Asselain, B, Barlow, W, Bartlett, J et al. (107 more authors) (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer : meta-analysis of individual patient data from ten randomised trials. The Lancet Oncology, 19 (1). pp. 27-39. ISSN 1470-2045

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Alberro, JA, Ballester, B et al. (596 more authors) (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. The Lancet Oncology, 19 (1). pp. 27-39. ISSN 1470-2045

Martin, M, Holmes, FA, Ejlertsen, B et al. (32 more authors) (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 18 (12). pp. 1688-1700. ISSN 1470-2045

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman, R, Powles, T et al. (102 more authors) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet, 386 (10001). 1353 - 1361. ISSN 0140-6736